Company Description
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Austria GmbH
Stella-Klein-Löw-Weg 15/3
1020 Vienna
Austria
Phone: +43 1 484 4613
Fax: +43 1 484 4613 11
www.biogenidec.at
2012 represents the 123rd anniversary of Schülke&Mayr. There have been many changes over the years, but do you think the ideals and values of today reflect the original vision set…
What are the historical and strategic factors which position Austria as one of the best healthcare systems in the world today? The main principles of the Austrian health care system…
You have been with Bayer for almost 15 years. What would you say defines your loyalty to the company, and has the time so far met your original expectations? Bayer…
What have been the most significant developments as a result of the acquisition of Viatris by Meda Pharma in 2005? At that time Viatris was a small company, and there…
What initially attracted you to Biotest back in 2001 and what do you think attracts industry professionals to Biotest today? I started my pharmaceutical career at Behring in Austria, doing…
You previously worked as CSO for onepharm; what was the motivation for creating Savira? OS: When I was working at onepharm, the organization was focused on anti-influenza and anti-inflammatory drug…
You have been managing LEO Pharma’s Austrian operations since March 2012. How do you look back at these first few months? And what have been your first initiatives at the…
You have been the head of MSD’s Austrian operations since April 2009. Can you start by telling our readers about the evolution of the affiliate since the merger with Schering…
What have been the focus areas for the association in improving the wellbeing of the life science biotech industry and what have been the key milestones/achievements since 2008 in providing…
Dr Prchla, you have been heading Merck’s Austrian subsidiary over the past eighteen months. What do you see as the key strengths of your company today? Mirroring the company’s structure,…
Dr. Rumler, what is your assessment of the subsidiary’s current strengths and weaknesses, after three and half years of tenure? Pfizer currently ranks second in the overall pharmaceutical market in…
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
See our Cookie Privacy Policy Here
